Reports Q4 revenue $20.33M, consensus $21.4M. "2022 was truly a transformational year for Harrow," said Mark L. Baum, CEO of Harrow. "Our IHEEZO journey has been remarkable – with its FDA approval in September 2022, and recently, in 2023, its issuance of a permanent J-Code and Transitional Pass-Through Reimbursement payment status. We believe that the J-Code and Pass-Through designations will enable a more efficient reimbursement process for ophthalmologists, optometrists, and retina specialists and create greater accessibility to the many clinical benefits that IHEEZO provides. We are confident that the infrastructure investments we made throughout 2022 to strengthen our people, platform, and performance will greatly contribute to a successful launch of IHEEZO in May 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HROW:
- Harrow Health announces CMS approval for reimbursement status for Iheezo 3%
- Harrow gets transitional pass-through reimbursement status for IHEEZO from CMS
- Harrow Health dips 4% after Bonitas publishes short report
- Harrow Health named a short idea by Bonitas Research
- Harrow Health granted product-specific J-Code for Iheezo in ocular anesthesia
